Theravance Biopharma, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
In the September 2026 Zymeworks merger, Theravance Biopharma shareholders received one CVR per share. CVRs entitle holders to: (1) 80% of net license proceeds from CVR Product (ampreloxetine) deals by License Expiration Date (10 years post-close); (2) $0.93/CVR upon First Commercial Sale Milestone in a Major Market by that date; (3) 10% of net sales as royalties during the Royalty Term. No payments guaranteed unless a license deal executes and produces proceeds, or first sale occurs. Payments via Computershare; CVRs are non-transferable and non-voting.
Why this rating
CVRs are speculative future payments, not immediate cash. No guarantee of any payout; highly contingent on commercial milestones. Small relative to $448.6M market cap; typical M&A earnout structure.
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.